GlassScriptPhysician profile
Casi Norman
NPI 1205369121
$5,329.05
in general payments reported to CMS, 2019-2025
24 companies · $1,029 in 2025
The $1,029 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $654 · 2022: $1,635 · 2023: $1,561 · 2024: $449 · 2025: $1,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,040.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,039.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,974.76 | 2021-2025 | |
| Novo Nordisk INC | $931.34 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Janssen Biotech, INC. | $430.99 | 2024-2025 | Tremfya, Stelara |
| Amneal Pharmaceuticals LLC | $269.88 | 2021-2025 | Unithroid |
| Ironshore Pharmaceuticals INC. | $226.98 | 2022-2023 | Jornay Pm |
| Astellas Pharma US INC | $208.62 | 2024-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $206.88 | 2022 | |
| Shield Therapeutics INC | $197.33 | 2022-2025 | Accrufer |
| Merz North America, INC. | $87.60 | 2024-2025 | |
| Pfizer INC. | $85.50 | 2022-2024 | |
| Kowa Pharmaceuticals America, INC. | $82.10 | 2021-2023 | Livalo, Seglentis |
| Azurity Pharmaceuticals, INC. | $81.58 | 2023 | Adthyza |
| Ibsa Pharma INC. | $72.89 | 2021-2023 | Tirosint, Licart |
| Takeda Pharmaceuticals U.S.A., INC. | $65.68 | 2021-2023 | Trintellix |
| Therapeuticsmd, INC. | $56.05 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $55.09 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $50.80 | 2021 | |
| Lilly USA, LLC | $50.06 | 2021-2022 | |
| Virtus Pharmaceuticals LLC | $49.19 | 2021-2022 | |
| Corcept Therapeutics | $42.36 | 2023 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.82 | 2023 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $28.05 | 2021 | |
| Currax Pharmaceuticals LLC | $27.96 | 2021-2022 | |
| Acella Pharmaceuticals, LLC | $16.54 | 2025 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casi Norman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.